KRAS and cancer: Taken together with a varying degree of dependence of cancer cells on the presence of KRASG12C mutations for growth and survival, as well as the heterogeneity of intratumoral KRAS mutation expression, our data highlight the importance of combination strategies in overcoming treatment resistance.